News

The study of AFN-1252 will evaluate the safety, tolerability and pharmacokinetics of a single escalating oral dose. Affinium believes that AFN-1252 will provide patients and their doctors a

DAG Ventures led the round, which included investments from previous investors Kleiner Perkins Caufield & Byers, New Science Ventures, Integral Capital Partners, Aperture Venture Partners and Cross Creek

DM-99 is a biological product with a well established safety profile that is being studied by DiaMedica for a novel use as a treatment for type 2 diabetes.

The acquisition will complement Cardinal Health’s infection prevention offerings by adding a differentiated and proven product line to the company’s Medical Products and Technologies segment. Cardinal Health plans

The test measures for a substance known as HE4, which many studies have shown can be elevated in epithelial ovarian cancers. The test is intended to be used

The Canadian Intellectual Property Office has granted a patent for the process, formulation and use claims to a mixed micellar pharmaceutical formulation for buccal administration. The National Institute

Bioniche plans to start a Phase III clinical trial comparing Urocidin, to the current standard therapy in patients with non-muscle-invasive bladder cancer at high risk of recurrence or

The company seeks approval prior to the expiration of patents owned by Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals. Watson’s levonorgestrel and ethinyl estradiol product is a generic

In pursuing this path, company will continue to actively evaluate several structures to distribute to its stockholders 50% or more of the value of its future antibody humanization